241 active not recruiting. 241 Phase 1, 93 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 241 | Active not recruiting 241 |
| Phase 2 | 93 | Active not recruiting 93 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI [99mTc]Tc-HYNIC-FAPI - Lung Cancer (Locally Advanced or Metastatic), Pancreas Cancer, Metastatic | Phase 1 | Active not recruiting | Tomsk National Research Medical Center of the Russian Academy of Sciences | 15 | 2026-02-26 | 2026-06-25 |
| A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants BAT3306, US-Keytruda® - Carcinoma, Non-Small-Cell Lung | Phase 1 | Active not recruiting | Bio-Thera Solutions | 160 | 2025-10-14 | 2026-09-02 |
| A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors HLX17, US-sourced Keytruda® - Non-small Cell Lung Cancer, Melanoma | Phase 1 | Active not recruiting | Shanghai Henlius Biotech | 174 | 2025-09-26 | 2026-10-20 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) YL201, Tarlatamab, Durvalumab - Small Cell Lung Cancer | Phase 1 | Active not recruiting | Amgen | 29 | 2025-05-16 | 2026-05-20 |
| Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 Trabedersen, Pembrolizumab - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Nebraska | 45 | 2025-05-12 | 2026-09-25 |
| A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC RC148 plus Carboplatin and Paclitaxel/pemetrexed, RC148 - Non-Small Cell Lung Cancer | Phase 1 | Active not recruiting | RemeGen Co., Ltd. | 121 | 2025-03-13 | 2026-03-05 |
| Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Ivonescimab Combined With Chemotherapy - Malignant Pleural Mesothelioma, Advanced | Phase 1 | Active not recruiting | Ruijin Hospital | 9 | 2025-03-12 | 2026-11-02 |
| Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy 225Ac-ABD147 - Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Active not recruiting | Abdera Therapeutics Inc. | 17 | 2025-03-10 | 2026-04-24 |
| KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors KRAS-specific Autologous TCR-T cell injection - Colorectal, Pancreatic | Phase 1 | Active not recruiting | Corregene Biotechnology Co., Ltd | 8 | 2025-02-18 | 2026-03-25 |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors BMS-986490, Bevacizumab - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 360 | 2025-02-12 | 2026-09-01 |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) M9140 - Solid Tumors, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 184 | 2025-01-29 | 2026-10-22 |
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors IPH4502 - Advanced or Metastatic Solid Tumors | Phase 1 | Active not recruiting | Innate Pharma | 145 | 2025-01-24 | 2026-11-03 |
| A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations valemetostat tosylate, pembrolizumab - Non-small Cell Lung Cancer, Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | Daiichi Sankyo | 137 | 2024-10-30 | 2026-07-28 |
| A Study of DM001 in Patients With Advanced Solid Tumors DM001 - Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Active not recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | 128 | 2024-10-24 | 2026-08-28 |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors LY4066434., Cetuximab, Nab paclitaxel - Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 750 | 2024-10-21 | 2026-07-20 |
| A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors BMS-986484, Nivolumab, Oxaliplatin - Advanced Solid Tumors | Phase 1 | Active not recruiting | Bristol-Myers Squibb | 213 | 2024-10-10 | 2026-04-17 |
| Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors MNPR-101-PCTA-177Lu - Solid Tumor, Adult, Bladder Cancer | Phase 1 | Active not recruiting | Monopar Therapeutics | 12 | 2024-10-08 | 2026-09-03 |
Showing 20 of 241. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (179) · Lung Neoplasms (75) · Colorectal Neoplasms (48) · Melanoma (45) · Neoplasms (36) · Ovarian Neoplasms (35) · Squamous Cell Carcinoma of Head and Neck (34) · Stomach Neoplasms (33) · Neoplasm Metastasis (32) · Small Cell Lung Carcinoma (28) · Triple Negative Breast Neoplasms (28) · Carcinoma, Renal Cell (27) · Pancreatic Neoplasms (26) · Breast Neoplasms (25) · Endometrial Neoplasms (20)
Neoplasms by Site (238) · Respiratory Tract Neoplasms (237) · Lung Diseases (234) · Respiratory Tract Diseases (234) · Neoplasms (205) · Carcinoma, Bronchogenic (197) · Bronchial Neoplasms (196) · Lung Neoplasms (165) · Neoplasms by Histologic Type (107) · Neoplasms, Glandular and Epithelial (92) · Digestive System Diseases (84) · Digestive System Neoplasms (83) · Skin Diseases (82) · Skin and Connective Tissue Diseases (82)
pembrolizumab (52) · Carboplatin (25) · Nivolumab (20) · Pemetrexed (17) · Cisplatin (15) · osimertinib (12) · Gemcitabine (10) · Fluorouracil (9) · Magnetic Resonance Spectroscopy (9) · Paclitaxel (9) · atezolizumab (9) · Bevacizumab (8) · Cetuximab (8) · Cyclophosphamide (8) · Docetaxel (8)
National Cancer Institute (NCI) (19) · M.D. Anderson Cancer Center (14) · AstraZeneca (9) · Eli Lilly and Company (8) · Memorial Sloan Kettering Cancer Center (8) · Jonsson Comprehensive Cancer Center (6) · AbbVie (5) · Amgen (5) · Boehringer Ingelheim (5) · Daiichi Sankyo (5) · Novartis Pharmaceuticals (5) · Sichuan Baili Pharmaceutical Co., Ltd. (5) · H. Lee Moffitt Cancer Center and Research Institute (4) · Janssen Research & Development, LLC (4) · Bristol-Myers Squibb (3)
United States (199) · Spain (70) · France (55) · South Korea (50) · Australia (46) · Japan (46) · Canada (43) · China (43) · Italy (36) · United Kingdom (32) · Germany (31) · Taiwan (31) · Belgium (24) · Netherlands (17) · Poland (17)
Anne S Tsao (3) · Caicun Zhou, PHD (2) · David Hong, MD (2)
PMID 22225488, PMID 22285199, PMID 29518553, PMID 31386610, PMID 32002290, PMID 32771088, PMID 32846060, PMID 32846061, PMID 33001143, PMID 33122578, PMID 34088726, PMID 34339261, PMID 34339292, PMID 34427115, PMID 34491815, PMID 34561039, PMID 34746886, PMID 35045358, PMID 35614486, PMID 35688554, PMID 35690072, PMID 35717027, PMID 35729005, PMID 35756843, PMID 35815644, PMID 35929986, PMID 35930972, PMID 35963523, PMID 36108661, PMID 36122315, PMID 36399068, PMID 36537204, PMID 36624315, PMID 36641093, PMID 36652175, PMID 36657661, PMID 36991390, PMID 36997799, PMID 37022784, PMID 37265412, PMID 37327461, PMID 37363992, PMID 37384848, PMID 37491889, PMID 37501016, PMID 37589131, PMID 37589506, PMID 37590355, PMID 37592303, PMID 37611121
2023 (20), 2018 (7), 2019 (6), UM1CA186717 (6), UM1CA186689 (4), UM1CA186690 (4), 2025 (3), U10CA180888 (3), 2015 (2), P30CA033572 (2), U10CA032102 (2), UM1CA186644 (2), UM1CA186686 (2), UM1CA186691 (2), UM1CA186709 (2)